Key Stats for Intuitive Surgical Stock
- Current Price: $394.51
- Target Price (Mid): ~$624
- Street Target: ~$478
- Potential Total Return: ~58%
- Annualized IRR: ~11% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Intuitive Surgical (ISRG) closed August 14 at $394.51, down about 30% for the year and roughly 20% above its 52-week low of $328.57. The slide has run most of 2026, but it turned violent in late July, deepening to a 44% drawdown from the stock’s 2025 peak. Two events drove that leg down. Management posted a clean Q2 beat after the close on July 16, and the stock fell 14% the next session, because the beat came with full-year guidance that the company declined to raise. Six days later, the FDA cleared Johnson & Johnson’s Ottava robot for ten general-surgery procedures, the first credible challenger in soft-tissue surgery, da Vinci’s core turf, in two decades.
A business that just grew revenue 19% is worth a third less than it was in January, and investors have to decide whether the reprice reflects real damage or a rare discount on the company that invented robotic surgery. The answer depends on what the drawdown is actually pricing.
The Competitive Threat Finally Has a Product Behind It
For years, the bear case on Intuitive was abstract: someday, a large competitor would arrive. That someday is here. Ottava’s arms are built into the operating table rather than mounted on separate carts, cutting the floor space a program needs by up to half, and J&J has announced an immediate U.S. launch with Western Europe and Japan to follow.
HSBC cut the stock to Hold and slashed its target from $604 to $391 within days of the clearance, while Morgan Stanley moved to Buy in the same week, and UBS initiated at Buy. When respected desks reach opposite conclusions on one event, the disagreement is itself the signal: nobody yet knows how fast a rival converts clearance into installed systems. History offers one data point. Medtronic’s Hugo won FDA clearance for urology in December 2025, and JPMorgan’s Robbie Marcus said his August surgeon checks still point to Intuitive as the clear favorite, with no sign of share loss in that specialty.
See historical and forward estimates for Intuitive Surgical stock (It’s free!) >>>
Why 85% of the Revenue Is Harder to Take Than It Looks
Recurring revenue, meaning the instruments, accessories, and service a hospital buys every time a machine is used, reached $2.47 billion in Q2 and made up 85% of the total. That is the moat. A rival winning a capital sale places one system in one hospital. It does not move the millions of procedures already running on the 11,710 da Vinci systems installed worldwide as of June 30, because those cases are performed by surgeons and operating-room teams trained on da Vinci.
CFO Jamie Samath put the switching reality in concrete terms, noting that “around 70-ish percent of the systems acquired in the U.S. are under leasing arrangements.” Those contracts lock customers into the full Intuitive ecosystem for years rather than a one-off box. Displacement, then, is a retraining project for an entire surgical team, repeated hospital by hospital. The quarter did not read like a company losing its grip: revenue rose 19% to $2.89 billion, da Vinci procedures grew 15%, placements climbed 18% to 468 systems, and non-GAAP operating margin held at 42%, a level hard to sustain if Ottava were already biting.
The Softer Spot Sits in U.S. Procedure Growth
U.S. da Vinci procedure growth slowed to 12% in Q2 from 14% in Q1, and management tied part of that to patients deferring care as enhanced ACA premium subsidies expired, while bariatric cases pressured by GLP-1 drugs fell in the high single digits. That is why the guidance hold stung: keeping full-year procedure growth at 13.5% to 15.5% after a strong first half told investors management expects the back half to slow.
Samath was careful not to overstate the ACA effect, calling it “likely some combination” of subsidy expiration and “the law of large numbers.” He stressed the demand does not vanish, noting the underlying disease burden is unchanged and deferred conditions ultimately require treatment. That frames the slowdown as timing rather than lost volume. International held up, with procedures outside the U.S. up 20% and newer platforms carrying their weight as SP grew 61% and Ion 36%.
See how Intuitive Surgical performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $394.51
- Target Price (Mid): ~$624
- Potential Total Return: ~58%
- Annualized IRR: ~11% / year
See analysts’ growth forecasts and price targets for Intuitive Surgical stock (It’s free!) >>>
Revenue drivers: double-digit da Vinci procedure growth as the installed base compounds, plus the faster ramp of newer platforms like SP and Ion.
Margin driver: operating leverage, with net income margins holding around 32% as the installed base scales, fixed costs faster than variable spending grows.
Primary risk: Ottava and Hugo eroding pricing power on capital equipment, compressing the multiple, and slowing recurring revenue growth.
The upside case: procedure deferral proves temporary, da Vinci 5 adoption reaccelerates, and the shares re-rate toward the target. The downside case: U.S. softness persists into 2027, and the multiple keeps grinding lower even as earnings grow. The model runs from the current $394.51, near the low of the 52-week range.
Conclusion
The one number that decides the near-term debate is the U.S. da Vinci procedure growth. It slowed to 12% in Q2, and guidance implies the back half stays around there or dips. Intuitive’s Q3 report, expected in late October, is the test. Growth stabilizing at or above the low-teens would signal the ACA deferral was a timing blip and hand the bulls their re-rating case. A step down toward high single digits would suggest the U.S. slowdown is structural, and no amount of recurring revenue fixes a decelerating core. Watch that one line in October, before the Ottava story has produced a single quarter of real placement data.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Intuitive Surgical?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Intuitive Surgical, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Intuitive Surgical alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Intuitive Surgical on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
